Investors have been keeping a sharp eye on Bristol Myers as its stock has lagged behind peers recently. Bristol Myers’ stock ...

Bristol-Myers Squibb is testing MORAb-202 in a Phase 2 trial to challenge traditional chemotherapy for platinum-resistant ...

Patient-Assistance Programs: Assessment of and Use by Safety-Net Clinics Kathryn Saenz Duke; Kristiana Raube; Helene Levens Lipton Disclosures Am J Health Syst Pharm. 2005;62 (7):726-731.

It is the first selective TYK2 inhibitor in clinical studies across multiple immune-mediated diseases. Bristol Myers Squibb scientists designed Sotyktu to selectively target TYK2, thereby inhibiting ...

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Sotyktu significantly outperformed placebo for the treatment of psoriatic arthritis in a phase 3 trial, meeting key endpoints at 16 weeks, according to late-breaking data presented at the American ...

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of a new Opdivo (nivolumab) formulation ...

Bristol Myers Squibb announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque ...

Bristol Myers filed its lawsuit in U.S. District Court for the District of Columbia and challenges HRSA's determination that BMS’s intended rebate model would be inconsistent with the 340B ...

STAT’s Matthew Herper picked Bristol Myers Squibb CEO Chris Boerner’s brain at the STAT Summit on all things related to the Inflation Reduction Act, and the upcoming election.